Five recent developments in psoriasis

Research finding that there was a significantly reduced risk for new-onset and progression of psoriasis associated with gastric bypass in patients undergoing bariatric surgery was among recent developments reported on Healio.com/Dermatology.

Other developments included findings that biologics for psoriasis may increase the risk of squamous cell carcinoma and that Stelara had higher retention rates than other biologics in patients with psoriasis:

Biologics for psoriasis may increase risk of squamous cell carcinoma

Patients with psoriasis who were treated with biologics had an increased incidence of cutaneous squamous cell carcinoma, according to study results recently published in the Journal of the American Academy of Dermatology. Read more

Stelara had higher retention rates than other biologics in patients with psoriasis

Stelara had better retention rates when compared with other biologics in the treatment of patients with severe psoriasis, according to study results published in the Journal of the American Academy of Dermatology.

Researchers used the database of Clalit Health Services, the largest public HMO in Israel, to perform survival analysis on 907 patients (40% female; mean age, 46.3 years) with severe psoriasis who received treatment of Humira (adalimumab, AbbVie), Remicade (infliximab, Janssen), Enbrel (etanercept, Amgen) and Stelara (ustekinumab, Janssen). Read more

CMS issues payment information for biosimilar Inflectra

CMS has included payment information for Inflectra, the FDA-approved biosimilar to Janssen’s Remicade, in its January Average Selling Price pricing file, Pfizer announced.

The FDA approved infliximab-dyyb (Inflectra, Celltrion) in April 2016. It is the second biosimilar to be approved in the U.S., the first biosimilar to infliximab (Remicade, Janssen), and the first biosimilar monoclonal antibody available in the U.S. Read more

IBD uncommon with Taltz treatment for psoriasis

Crohn’s disease and ulcerative colitis were uncommon in patients with psoriasis who were treated with Taltz in seven clinical trials, according to data recently published in the Journal of the American Academy of Dermatology.

Researchers analyzed adverse events through April 9, 2015, that were integrated from seven randomized controlled and uncontrolled trials of patients with moderate-to-severe psoriasis. Read more

Gastric bypass associated with reduced risk for psoriasis, psoriatic arthritis

There was a significantly reduced risk for new-onset and progression of psoriasis and psoriatic arthritis associated with gastric bypass in patients undergoing bariatric surgery, but gastric banding did not have the same association.

Researchers used data from the Danish National Patient Registry to identify all Danish citizens who underwent gastric bypass or gastric banding between Jan. 1, 1997 and Dec. 31, 2012. Read more